FDA’s 2026 Guidance on General Wellness Devices: Policy for Low-Risk Devices— Key Compliance and Regulatory Insights for Digital Health Companies

Introduction
On January 6, 2026, the U.S. Food and Drug Administration (“FDA”) issued its updated
General Wellness: Policy for Low Risk Devices guidance
https://www.fda.gov/media/90652/download (the “2026 Guidance”), providing important
clarification on how general wellness products under the FDA policy are distinguished from
regulated medical devices.
For companies navigating digital health FDA regulation, including developers of
wearables, mobile applications, and software as a medical device (SaMD) wellness tool,
This 2026 Guidance is a critical roadmap. It reinforces that while the FDA continues to apply
enforcement discretion for wellness products, the dividing line between wellness vs.A
medical device under FDA standards remains highly dependent on intended use and
claims.
FDA’s General Wellness Policy: Enforcement Discretion for Low-Risk Devices
At its core, the FDA’s general wellness guidance 2026 reaffirms that the agency does not
intend to actively regulate certain low-risk medical devices that qualify as wellness
products. This reflects the FDA’s broader policy of enforcement discretion for wellness
products, particularly in the rapidly evolving digital health ecosystem.
To qualify under the general wellness products FDA policy, a product must meet two key
criteria:

1. General Wellness Intended Use (FDA Intended Use Standard)
   The product must be intended solely to:
       •    Promote a healthy lifestyle (e.g., fitness, sleep, stress management); or
       •    Support general wellness without making disease-specific claims
   Under the FDA intended use medical device framework, even indirect or implied claims
   can trigger device classification. For example, statements linking a product to treatment,
   diagnosis, or mitigation of a disease may move the product outside the wellness
   category.
2. Low Risk to Users (Low-Risk Medical Devices FDA Standard)
   The product must present minimal risk, meaning it is:
       •    Non-invasive
       •    Not implanted

    •    Not dependent on high-risk technologies
Only products meeting this threshold fall within the low-risk medical devices, FDA
wellness category.
Key Updates in FDA’s 2026 General Wellness Guidance
The 2026 Guidance reflects a significant modernization of how the agency views digital
health products and wearable device compliance.
Expanded Scope for Wearable Devices and Physiological Monitoring
FDA now recognizes that certain wearable devices that comply with FDA considerations allow
for broader functionality within the wellness category.
Examples include:
    •    Heart rate monitoring
    •    Sleep tracking
    •    Activity and recovery metrics
    •    General biometric trend tracking
Even more advanced metrics—such as oxygen saturation or blood pressure
trends—may fall within the software as a medical device wellness category, provided
they are:
    •    Non-diagnostic
    •    Not tied to disease claims
    •    Not used for clinical decision-making
This reflects the FDA’s evolving approach to digital health FDA regulation, particularly for
consumer-facing technologies.
Increased Clarity for Digital Health and SaMD Wellness Tools
The 2026 Guidance confirms that many digital health platforms and software as a
medical device (SaMD) wellness product may qualify for enforcement discretion when:
    •    Outputs are informational only
    •    No clinical interpretation is provided
    •    Recommendations remain general and lifestyle-focused

This is particularly relevant for:
    •    AI-driven wellness platforms
    •    Consumer health dashboards
    •    Lifestyle and coaching applications
Permissible Messaging and Notifications
Under the general wellness products FDA policy, companies may:
    •    Encourage users to consult healthcare professionals
    •    Provide general benchmarks or ranges
However, under FDA intended use medical device principles, products may not:
    •    Provide diagnostic alerts
    •    Trigger clinical interventions
    •    Recommend treatment
This is a key area of risk in the wearable device compliance FDA strategy, particularly in
app notifications and user interfaces.
Drawing the Line: Wellness vs. Medical Device (FDA Analysis)
A central theme of the 2026 Guidance is the importance of distinguishing wellness vs.
medical device FDA classification.
A product is likely to be regulated if it:
    •    References specific diseases
    •    Provides diagnostic or predictive outputs
    •    Uses clinical or medical terminology
    •    Claims “medical-grade” accuracy
    •    Functions as a substitute for a regulated device
Even where technology remains unchanged, the FDA intends to use medical device analysis
can shift classification based solely on:
    •    Marketing language
    •    Labeling
    •    Product design

What Remains Regulated
The 2026 Guidance does not:
    •    Exempt products that otherwise meet the definition of a medical device
    •    Apply to drugs, biologics, or combination products
    •    Override FTC or state law requirements
Companies must still ensure compliance with:
    •    Truth-in-advertising standards
    •    Substantiation requirements
    •    Broader digital health FDA regulation frameworks
Practical Compliance Considerations

1. Claims and Positioning Drive Risk
   Under the FDA intended use medical device framework, regulatory status is determined
   largely by:
       •    Website and promotional claims
       •    Product labeling
       •    App store descriptions
   A consistent general wellness positioning strategy is essential.
2. Product Design Must Align with Wellness Use
   Features such as:
       •    Alerts
       •    Notifications
       •    Data outputs
   Clinical use implications must be avoided. This is a key issue in wearable device
   compliance FDA reviews.
3. Plan for Transition to Regulated Products
   Many companies begin within the general wellness products FDA policy but later
   expand into:
       •    Clinical applications

    •    Remote patient monitoring
    •    Regulated SaMD pathways
Early alignment with digital health FDA regulation strategy is critical.
Key Takeaways
    •    The 2026 Guidance expands flexibility for low-risk medical devices FDA
classification
    •    Wearable device compliance FDA standards now allow broader physiological
monitoring within wellness
    •    Software as a medical device wellness tools can qualify if properly positioned
    •    FDA enforcement discretion wellness products remains highly dependent on
claims and intended use
    •    The distinction between wellness vs. medical device FDA classification is driven
by how products are marketed and used
Conclusion
The 2026 Guidance represents a significant step forward in aligning digital health FDA
regulation with modern technology.
For companies developing wearables, mobile health apps, and software as a medical
device wellness products, the opportunity to operate within the general wellness
products FDA policy is substantial—but requires disciplined compliance strategy.
Ultimately, success depends on a clear understanding of FDA intended use medical
device principles, thoughtful product design, and precise marketing execution to remain
within the low-risk wellness category.